key: cord-0724616-bm0b98pa
authors: Liu, Hejun; Yuan, Meng; Huang, Deli; Bangaru, Sandhya; Zhao, Fangzhu; Lee, Chang-Chun D.; Peng, Linghang; Barman, Shawn; Zhu, Xueyong; Nemazee, David; Burton, Dennis R.; van Gils, Marit J.; Sanders, Rogier W.; Kornau, Hans-Christian; Reincke, S. Momsen; Prüss, Harald; Kreye, Jakob; Wu, Nicholas C.; Ward, Andrew B.; Wilson, Ian A.
title: A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
date: 2021-04-15
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.04.005
sha: 254d3c7b90a27b95ee2cf956b357f27f5beec94d
doc_id: 724616
cord_uid: bm0b98pa

Coronaviruses have caused several human epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic antibodies have already shown striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as well as threats from other sarbecoviruses. Cross-neutralizing antibodies to SARS-related viruses provide opportunities to address such concerns. Here, we report on crystal structures of a cross-neutralizing antibody CV38-142 in complex with the receptor binding domains from SARS-CoV-2 and SARS-CoV. Recognition of the N343 glycosylation site and water-mediated interactions facilitate cross-reactivity of CV38-142 to SARS-related viruses, allowing the antibody to accommodate antigenic variation in these viruses. CV38-142 synergizes with other cross-neutralizing antibodies, notably COVA1-16, to enhance neutralization of SARS-CoV and SARS-CoV-2, including circulating variants of concern B.1.1.7 and B.1.351. Overall, this study provides valuable information for vaccine and therapeutic design to address current and future antigenic drift in SARS-CoV-2 and protect against zoonotic SARS-related coronaviruses.

Severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2, have caused epidemics in the past two decades including the current pandemic of coronavirus disease 2019 . SARS-CoV-2 has already resulted in more than 130 million reported cases and almost 2.9 million deaths worldwide as of the beginning of April 2021 (https://covid19.who.int). Although these viruses have devastating consequences in the human population, they are of animal origin and have less morbidity or even no symptoms in their animal hosts (Cui et al., 2019; Tortorici and Veesler, 2019; Ye et al., 2020) . In addition to these human β-coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2), other SARS-related coronaviruses (SARSr-CoVs) of the sarbecovirus subgenus within the β-coronavirus genus are found in mammalian reservoirs, such as bats and pangolins, and could also constitute potential pandemic threats to human health (Hu et al., 2015; Lam et al., 2020; Wacharapluesadee et al., 2021; Ye et al., 2020) . Recently, mutations in SARS-CoV-2 were identified in farmed mink and these viruses were found to be reciprocally transmissible between humans and farmed mink (Welkers et al., 2021) , further underscoring concerns about the long-term efficacy of current antibody therapies and vaccines under development (Mallapaty, 2020) . Hence, identification and characterization of cross-neutralizing antibodies within the sarbecovirus subgenus are of value for design and development of therapeutics and next generation vaccines to mitigate against antigenic drift as well as future SARSr-CoV transmission to humans from the mammalian reservoir.

Since the spike protein is the major surface protein on sarbecoviruses, neutralizing antibodies are targeted towards the spike and many of these antibodies are able to prevent virus interaction with the host receptor, angiotensin-converting enzyme 2 (ACE2) (Piccoli et al., 2020; Yuan et al., 2021b) . Other inhibition mechanisms also seem to be possible and are being assessed for other subsets of antibodies (Hansen et al., 2020; Piccoli et al., 2020; Pinto et al., J o u r n a l P r e -p r o o f 2 2020). The receptor binding domain (RBD) of the spike protein is highly immunogenic and can induce highly specific and potent neutralizing antibodies (nAbs) against SARS-CoV-2 virus (Barnes et al., 2020a; Barnes et al., 2020b; Brouwer et al., 2020; Cao et al., 2020; Ju et al., 2020; Kreye et al., 2020; Piccoli et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Yuan et al., 2020a; Zost et al., 2020) . Many of these nAbs bind to the receptor binding motif (RBM) on the RBD (Yuan et al., 2021b) . However, the breadth of these nAbs is limited as the RBM shares relatively low sequence identity among sarbecoviruses; the RBM is only 48% conserved between SARS-CoV-2 and SARS-CoV compared to 73% for the complete RBD (84% identity for non-RBM regions of the RBD). The RBD is also prone to naturally occurring mutations, along with the N-terminal domain (NTD) and other non-RBD and non-NTD regions, where insertions and deletions have also been found (Greaney et al., 2021b; Kemp et al., 2021; Liu et al., 2021; McCarthy et al., 2021; Starr et al., 2020; Tegally et al., 2021; Van Egeren et al., 2020; Voloch et al., 2021) . Recent studies showed that many potent monoclonal neutralizing antibodies are sensitive to the antigenic drift or mutation on the RBD of the spike protein (Thomson et al., 2021; Wang et al., 2021a; Wang et al., 2021b; Weisblum et al., 2020; Wibmer et al., 2021) , as well as polyclonal sera from convalescent or vaccinated individuals (Andreano et al., 2020; Greaney et al., 2021a; Liu et al., 2021; Wang et al., 2021a; Wang et al., 2021b; Weisblum et al., 2020; Wu et al., 2021) .

We and others have reported cross-neutralizing antibodies such as COVA1-16, H014, EY6A, S304 that bind to a highly conserved cryptic site in receptor binding domain (RBD) of the spike Lv et al., 2020; Piccoli et al., 2020; Yuan et al., 2021b; Zhou et al., 2020). 4 and SARS-CoV with similar potency (3.5 and 1.4 μg/ml) ( Figure 1B) . The roughly comparable binding to RaTG13 and Guangdong pangolin coronavirus RBDs suggests that CV38-142 may also neutralize these zoonotic SARS-related viruses (SARSr viruses). Of note, the CV38-142 Fab exhibits much weaker or no neutralization in the same assay, which suggests that the avidity of bivalent CV38-142 IgG plays a crucial role in the neutralization ( Figure 1B ) as we also observed in other antibodies such as COVA1-16 .

Recent reports on SARS-CoV-2 mutations in both human and mink populations give rise to concerns about viral escape from current vaccines and therapeutics in development (Andreano et al., 2020; Greaney et al., 2021a; Kemp et al., 2021; Mallapaty, 2020; Oude Munnink et al., 2021; Tegally et al., 2021; Voloch et al., 2021) . However, antibody cocktails that bind to distinct epitopes can increase neutralization breadth and may help prevent escape mutations Du et al., 2020; Greaney et al., 2021b; Hansen et al., 2020; Koenig et al., 2021) . We previously reported that CV38-142 does not compete for RBD binding with other potent antibodies in our sample set, which are encoded by diverse germline genes, such as CV07-200 (IGHV1-2), CV07-209 (IGHV3-11), CV07-222 (IGHV1-2), CV07-250 (IGHV1-18), CV07-262 (IGHV1-2), CV38-113 (IGHV3-53), and CV38-183 (IGHV3-53) (Kreye et al., 2020) . Here, we show that CV38-142 can bind either SARS-CoV-2 RBD or spike protein at the same time in a sandwich assay as CC12.1 and COVA2-39 (Figure 2A ), which are potent IGHV3-53 neutralizing antibodies from different cohorts Rogers et al., 2020) . Since CC12.1 (Yuan et al., 2020a) , as well as COVA2-39 and CV07-250 (Kreye et al., 2020) , bind to the RBM, these data suggest that CV38-142 can be combined with potent RBM antibodies derived from diverse germlines in an antibody cocktail. Hence, we tested whether CV38-142 could bind RBD at the same time as two other potent cross-neutralizing antibodies that target other sites on the RBD (Yuan et al., 2021b) . The sandwich binding assay revealed J o u r n a l P r e -p r o o f 5 that CV38-142 competes with S309 from a SARS patient , but is compatible with COVA1-16, a cross-neutralizing antibody to the CR3022 site isolated from a COVID-19 patient ( Figure 2A ) . We then assembled a cocktail consisting of different amounts and ratios of CV38-142 and COVA1-16. The cocktail showed enhanced potency in the 2D neutralization matrix assay with SARS-CoV-2 and enhanced potency and improved efficacy with SARS-CoV pseudoviruses, demonstrating that CV38-142 is a promising candidate for pairing with cross-neutralizing antibodies to the highly conserved CR3022 cryptic site ( Figure   2B ). For example, 100% inhibition in the neutralization assay could be achieved with 1.6 μg/ml of each of CV138-142 and COVA1-16 with SARS-CoV-2 compared to >200 μg and 40 μg/ml for the individual antibodies, respectively. For SARS-CoV, the corresponding numbers were higher and required 200 μg/ml of each antibody to approach 100% inhibition, where 200 μg only achieved 77% and 28% neutralization, respectively, for each individual antibody. These changes in potency and efficacy suggest synergy between CV38-142 and COVA1-16.

Synergistic neutralization effects have been analyzed in other viruses (Zwick et al., 2001) , including coronaviruses (ter Meulen et al., 2006; Zost et al., 2020) , and can be quantified by several algorithms using multiple synergistic models (Ianevski et al., 2017; Wooten and Albert, 2020) . Using the most up to date synergy model, our data analysis showed synergistic potency (α>1) between CV38-142 and COVA1-16 in two directions against both SARS-CoV-2 and SARS-CoV pseudoviruses, which suggests reciprocal synergy between CV38-142 and COVA1-16 ( Figure S1 ). Addition of COVA1-16 also improved the maximal efficacy of CV38-142 in neutralizing SARS-CoV as indicated by the positive synergistic efficacy score (β>0) ( Figure S1 ) as well as the neutralization matrix ( Figure 2B ).

We then determined the crystal structure of SARS-CoV-2 RBD in complex with CV38-142 and COVA1-16 Fabs at 1.94 Å resolution ( Figure 3A and Figure S2A , Table S1 ). COVA1-16 binds to J o u r n a l P r e -p r o o f 6 a highly conserved epitope on RBD in the same approach angle as we reported before . However, CV38-142 binds to a less conserved surface with no overlap with the COVA1-16 epitope and involves the N-glycosylation site at N343 on the RBD that is distal to the RBM ( Figure 3A and Figure S2A ). This N343 glycosylation site is conserved in sarbecoviruses ( Figure S3 ). The crystal structure showed well-resolved density for four of the sugar moieties attached to N343 ( Figure S4A ). Several hydrogen bonds are made to the glycan from both heavy and light chain ( Figure 3B ). The V H S100 amide hydrogen bonds to the posttranslationally modified N343, and V H R96, V L Y49 and V L S53 hydrogen bond to the core fucose moiety of the glycan as well as water molecules that mediate interactions between CV38-142 and glycan. These interactions contribute to binding between CV38-142 and SARS-CoV-2 RBD as glycan removal from the RBD using PNGase F, or with RBD expressed in HEK293S cells that results in high mannose glycans with no core fucose, results in a decrease in binding to CV38-142 from a K D of 27 nM to 42nM and 168 nM ( Figure 3C and Figures S2B-C). Glycan removal resulted in only a slight decrease in binding to SARS-CoV elicited antibody S309 ( Figure S2E ), which also interacts with the N343 glycan in SARS-CoV-2 RBD . To eliminate glycosylation at the N343 site, mutations were introduced into the NxT sequon either at asparagine or threonine residue in both SARS-CoV-2 and SARS-CoV RBDs.

An enzyme-linked immunosorbent assay (ELISA) showed a significant drop in binding of CV38-142 to both SARS-CoV-2 and SARS-CoV RBD, while antibody binding to other epitopes, such as CR3022 and CV07-209, were not impacted ( Figure S2D ). Deep mutational scanning on SARS-CoV-2 RBD previously indicated lower expression of mutants with changes near the glycosylation site, especially at residue 343 (Starr et al., 2020) . We therefore used S309 as a probe to show the epitope surface is exposed and can be recognized by S309 ( Figure S2D ). S309 is less affected by the absence of the N343 glycan as mutation in the NxT sequon at residue 345 had minor impact on S309 binding to the RBD, although there was a significant drop in binding to SARS-CoV-2 RBD N343Q ( Figure S2D ). Residue 343 also appears to be less J o u r n a l P r e -p r o o f 7 tolerant of mutations than residue 345 (Starr et al., 2020) . These findings suggest that the complex glycan at N343 Watanabe et al., 2020) contributes to RBD binding by CV38-142, especially with its core fucose, rather than simply acting as a glycan shield to antibodies.

In addition to the N343 glycan, interactions with other residues are observed between CV38-142 and SARS-CoV-2 RBD. The V H R58 guanidinium hydrogen bonds to the L441 backbone carbonyl in SARS-CoV-2, while its hydrophobic portion interacts with the alkene region of K444. V H W100c indole hydrogen bonds with the N440 carbonyl and forms a hydrophobic patch with V H V98 and the L441 side chain in SARS-CoV-2 ( Figure 4A ). The V H S55 backbone carbonyl oxygen hydrogen bonds to the N450 amide ( Figure 4A ). Besides heavychain interactions, the V L Y92 carbonyl oxygen hydrogen bonds to the N440 side chain in SARS-CoV-2 RBD. Overall, CV38-142 interacts with RBD mainly through its heavy chain, which contributes 79% of the buried surface area (BSA) on the RBD (629 Å 2 out of 791 Å 2 total BSA as calculated by the PISA program, Figure 4B ). Eight polar interactions and two sites of hydrophobic interactions are involved in binding of CV38-142 to SARS-CoV-2 RBD (Table S2) .

The RBD residues involved in CV38-142 interaction with SARS-CoV-2 are not all identical in SARS-CoV RBD ( Figure S4 ). Eight of 20 residues differ in the CV38-142 epitope between SARS-CoV-2 and SARS-CoV. To investigate how CV38-142 accommodates these differences, we determined a crystal structure of CV38-142 Fab in complex with SARS-CoV RBD at 1.53 Å resolution ( Figure 3A , Table S1 ). CV38-142 binds SARS-CoV RBD at the same site with an identical approach angle, albeit interacting with some different residues in the RBD. Interaction with the conserved N330 glycan ( Figure 3B and Figure S2D ), and the conserved N427 and N437 ( Figure 4C ) are the same as with SARS-CoV-2. Similar hydrophobic interactions are J o u r n a l P r e -p r o o f 8 maintained with I428 in SARS-CoV RBD and L441 in SARS-CoV-2 RBD ( Figure 4C ). However, interactions with K444 are lost in CV38-142 binding to SARS-CoV RBD due a change to the corresponding T431 in SARS-CoV RBD (Table S2) . A hydrophilic surface of CDRH3 of CV38-142 is now juxtaposed to F360 of SARS-CoV RBD compared to S373 of SARS-CoV-2 RBD.

The phenyl moiety of F360 adopts heterogeneous conformations with diffuse electron density in the X-ray structure ( Figure S4E ). Side chains of other epitope residues of SARS-CoV RBD that differ from SARS-CoV-2 RBD are well adapted to the binding interface with no clashes or significant changes in the CV38-142 structure. Thus, the overall binding of CV38-142 to SARS-CoV RBD is essentially identical to SARS-CoV-2 ( Figures 1A and 3A ) despite a few differences in specific interactions (Figures 4A and 4C) . It would appear to be unusual that the binding between an antibody and antigen would be retained at the same level with half of the polar interactions being depleted in the interface of a cross-reacting protein (Table S2 ). One explanation is the abundance of water molecules mediating interaction between CV38-142 and both SARS-CoV-2 and SARS-CoV RBD. Many conserved water-mediated interactions are found with the peptide backbone in both SARS-CoV-2 and SARS-CoV RBD ( Figure 5 ). The structures here are at high enough resolution to confidently identify these bound water molecules ( Figure S4C -D). Water molecules have also been shown to be particularly important in other antibody-antigen interfaces (Braden et al., 1995; Wilson and Stanfield, 1993; Yokota et al., 2003) . The shape complementarity (SC) (Lawrence and Colman, 1993) between CV38-142 and SARS-CoV-2 or SARS-CoV (0.63 and 0.58, respectively) is lower than for the average for antibody-antigen interactions or protein-protein interactions (Kuroda and Gray, 2016) , when water molecules are not considered. Consistent with the SC analysis and high binding affinities, 24 water molecules mediate more than 60 hydrogen bonds between CV38-142 and SARS-CoV-2 RBD ( Figure 5A and Figure S4C ). A comparable number of water-mediated interactions are also observed with SARS-CoV RBD ( Figure 5B and Figure S4D ). These water-mediated interactions are mostly conserved in the interaction with CV38-142 with SARS-CoV-2 and J o u r n a l P r e -p r o o f SARS-CoV RBDs, with 15 that overlap and mediate interactions with both SARS-CoV-2 and SARS-CoV RBD ( Figure 5 ). Considering the contribution from these water molecules, the loss of some direct contacts between CV38-142 and SARS-CoV RBD may be partially compensated by these abundant water-mediated interactions, suggesting a potential mechanism whereby CV38-142 could resist antigenic drift.

Structure superimposition of ACE2 bound to RBD reveals no clash between ACE2 and CV38-142. The closest distance is 6 Å, which corresponds to the distance between the first NAG moiety of the ACE2 N53 glycan and the H66 imidazole of CV38-142 in the antibody complex with SARS-CoV-2 RBD ( Figure 4D ). There seems to be sufficient space for the remainder of the glycan to be accommodated due to the large open void between CV38-142 and ACE2. In addition, we observe some flexibility in this region (S60-H66) of CV38-142 that would allow even more room for the ACE2 N53 glycan if both ACE2 and CV38-142 were to bind RBD simultaneously ( Figure S5A ). BLI sandwich binding assays and the surface plasma resonance (SPR) competition assays revealed that binding of CV38-142 IgG does not occlude ACE2 binding to SARS-CoV-2 RBD or spike protein ( Figure 2A and Figure S5B ), suggesting no steric block between CV38-142 and ACE2. Since CV38-142 IgG potently neutralizes infection by SARS-CoV-2 and SARS-CoV pseudoviruses ( Figure 1B ) and in authentic virus assays (Kreye et al., 2020) , this finding then poses a question about the mechanism of CV38-142 neutralization of sarbecovirus infection. One explanation is that CV38-142 somehow attenuates ACE2 or other cofactor binding that cannot be observed in the sandwich binding assay or the SPR competition assay. We in fact previously reported that CV38-142 IgG reduced ACE2 binding to SARS-CoV-2 RBD by 27% in an enzyme-linked immunosorbent assay (ELISA) (Kreye et al., 2020) . The possible constraint on accommodating the N53 glycan in ACE2 upon J o u r n a l P r e -p r o o f simultaneous binding by CV38-142 IgG may contribute to this reduction on ACE2 binding in the ELISA assay (Kreye et al., 2020) .

Superimposition of the CV38-142 binding epitope onto a cryoEM structure of the spike trimer (PDB: 6VYB) suggests that CV38-142 is capable of binding RBD in both "up" and "down" states ( Figure 4B ). Consistent with this notion, 2D classification of the negative-stain electron microscopy (nsEM) images reveals that CV38-142 Fab can bind to SARS-CoV-2 or SARS-CoV spikes with various binding stoichiometries ( Figure S6A -B). The 3D reconstructions of both SARS-CoV-2 and SARS-CoV spikes indicated that CV38-142 Fab could bind RBDs in either "up" or "down" state ( Figure 6A and Figure S6C -D). The nsEM reconstructions also showed high flexibility of the RBD that only allowed reconstruction of partial density for the Fab ( Figure S6D ), suggesting heterogeneous conformations of the RBD when bound with CV38-142 Fab. Since the resolutions of the nsEM data are insufficient to build atomic models of spikes, we fit the crystal structure of CV38-142 Fab + SARS-CoV-2 RBD into the nsEM density map of SARS-CoV-2 spike bound to three CV38-142 Fabs in the two "down", one "up" state ( Figure 6A , pale blue). The tentative fitting model suggests a distance of 88 Å between the heavy chain C-termini of CV38-142 Fabs bound with RBD in "down" state and distances of 146 and 158 Å between the heavy chain C-terminal of CV38-142 Fab bound with RBD in "up" state and one of the RBDs in "down" state ( Figure 6B ).

For spike with RBDs in "2-up-1-down" state, we aligned CV38-142 Fab to the cryoEM structure of SARS-CoV-2 spike (PDB: 7CAI) (Lv et al., 2020) . Structural alignment suggests that the C-terminus of the CV38-142 Fab heavy chain points away from the spike center axis due to its particular approach angle ( Figure 6C ), echoing a similar observation in the nsEM reconstruction data. The distance among the C-termini ranges from 168-190 Å depending on the various combination of RBD states and similar to that measured in the nsEM fitting model J o u r n a l P r e -p r o o f ( Figure 6B ), indicating that it is not possible for an CV38-142 IgG to bind two RBDs bivalently in either two "up" or one "up", one "down" states within a spike trimer. For spike with RBDs in all "down" state, we aligned the crystal structure of CV38-142 Fab to a cryoEM structure of dimeric spike trimer (PDB: 7JJJ). The structural alignment reveals that the distance between any two Ctermini of CV38-142 Fab bound within a spike trimer is around 106 Å, which also suggests that CV38-142 is unlikely to bind two RBDs in the "down" state within a spike trimer ( Figure 6D ). On the other hand, CV38-142 Fabs can bind RBDs from two adjacent spikes in a dimer seen in Novavax vaccine candidate NVAX-CoV2373 with a distance of 26 Å between the C-termini of the Fabs, suggesting that a CV38-142 IgG can bind a dimeric spike, or two spikes that are close together, with its two Fabs bound to RBDs from neighboring spikes ( Figure 6D ). These analyses are in line with the neutralization data, where bivalency plays a critical role on neutralizing both SARS-CoV-2 and SARS-CoV infection as the Fab has much weaker to no inhibition against pseudovirus infection by these sarbecoviruses ( Figure 1B) .

To examine whether the combination of two cross-neutralizing antibodies has superior neutralization to individual antibodies, we tested a mixture of the two with a 1:1 molar ratio against the SARS-CoV-2 wild type (Wuhan-Hu-1) virus and two circulating variants of concern, i.e. B.1.1.7 and B.1.351, which escape from neutralization by many potent mAbs including some in emergency use authorization and by convalescent plasma from some patients Hoffmann et al., 2021; Wang et al., 2021a; Wibmer et al., 2021; Yuan et al., 2021a; Zhou et al., 2021) . The neutralization data showed that CV38-142 neutralizes both B. Kreye et al., 2020; Liu et al., 2020) .

We report here on a distinct cross-neutralizing epitope in the RBD for an anti-SARS-CoV-2 neutralizing antibody, CV38-142, that cross-reacts with other sarbecoviruses including SARS-CoV-2, SARS-CoV and SARS-related viruses in pangolins and bats ( Figure 1A and Figure S3 ). The epitope of CV38-142 is exposed to solvent regardless of whether RBD in the spike is in either the "up" or "down" states ( Figure 4B) . A SARS-CoV cross-neutralizing antibody S309, which has been previously characterized, binds to a nearby site and also interacts with the N343 glycan . Both CV38-142 and S309 bind to the same face of the RBD to partially overlapping epitopes ( Figure 3A and Figure S3 ) and compete with each other for RBD binding ( Figure 2A ). However, CV38-142 uses a different approach angle with its heavy and light chain rotated 90° around the epitope and N343 glycan site (N330 in SARS-CoV) compared to S309 ( Figure 3A ).

Binding of CV38-142 to the S309 epitope on the RBD allows simultaneous binding of RBM antibodies including those encoded by IGHV3-53 and other germlines (Kreye et al., 2020) as well as others tested in this study. Moreover, we also found that a particular combination of cross-neutralizing antibodies, namely CV38-142 and COVA1-16, to two different sites could synergize to enhance neutralization of both SARS-CoV-2 and SARS-CoV pseudoviruses. The crystal structure of the antibody cocktail in complex with SARS-CoV-2 revealed how two different cross-neutralizing antibodies can interact with the RBD without inhibiting each other J o u r n a l P r e -p r o o f 13 ( Figure S2 ). Our neutralization data indicated enhanced potency (i.e. half-maximal inhibitory concentration) and efficacy (maximum percentage of inhibition) with the cross-neutralizing antibody combination ( Figure 2B and Figure S1 ). The improved neutralization may arise from a synergistic effect on trapping the RBD in the up state since binding of COVA1-16 leads the RBD to tilt and twist in the up state . Since COVA1-16 is representative of crossneutralizing antibodies that bind to the CR3022 cryptic site (Yuan et al., 2021b) , other crossneutralizing antibodies identified so far (i.e. S304, H014, and EY6A) (Lv et al., 2020; Piccoli et al., 2020; Zhou et al., 2020) that also bind to the CR3022 site ( Figure S3 ) could also be paired with CV38-142 to improve cross-neutralization potency. The receptor binding site is quite diverse in sequence among SARS-CoV-2, SARS-CoV and other SARSr viruses and has already been subject to escape mutations; thus, antibodies to cross-neutralizing sites may provide better protection against antigenic drift, and therefore we did not focus on combinations of antibodies that include those targeting the RBM due to their sensitivity to RBM mutations in the recent variants of concern. Furthermore, although CV38-142 binds to a less conserved surface of the RBD across sarbecoviruses than COVA1-16, it uses fewer direct contacts and compensates through abundant water-mediated interactions that could accommodate antigenic differences and drift in sarbecoviruses. CV38-142 and COVA1-16 are capable of neutralizing the two main current variants of concern, i.e. B.1.1.7 and B.1.351. Combination of the two antibodies showed enhanced potency and efficacy in neutralizing SARS-CoV-2 as well as these variants of concern, thereby informing vaccine and antibody design and therapeutic use of such cross-neutralizing antibodies. Hence, our study provides valuable information to counteract potential escape mutations or antigenic drift in SARS-CoV-2, as well as future zoonotic viruses that could threaten global human health.

We thank Henry Tien for technical support with the crystallization robot, Jeanne Matteson and Yuanzi Hua for contribution to mammalian cell culture, Wenli Yu for insect cell culture, and Robyn Stanfield for assistance in data collection. We acknowledge BIAFFIN GmbH & Co KG (Kassel, Germany) for the help on the SPR competition assay. We are grateful to the staff of the Advanced Photon Source (APS) Beamline 23ID for assistance. This work was supported by the 

J o u r n a l P r e -p r o o f 15 A patent application for SARS-CoV-2 antibody CV38-142 was first disclosed in (Kreye et al., 2020) and filed under application number 20182069.3 by some of the authors at Neurodegenerative Diseases (DZNE) and Charité-Universitätsmedizin Berlin. The Amsterdam UMC filed a patent on SARS-CoV-2 antibodies including COVA1-16 under application number 2020-039EP-PR that included the AMC authors on this paper.

The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. Insertion in the right panel shows a zoomed-in view for Fabs/ACE2 binding on spike. A sandwich binding assay was used for the competition assay. CV38-142 IgG was first pre-loaded on the biosensor then SARS-CoV-2 RBD or spike was loaded at the indicated timepoint. The biosensors with captured antibody-antigen complex were tested against binding to a second antibody Fab or human ACE2. Loading events for RBD/spike and the second antibody Fab/ACE2 are indicated by arrows along the timeline (x-axis), while the binding response (nm, y-axis) was recorded in real time as colored lines corresponding to each antibody Fab or ACE2. 142 epitope is exposed to solvent regardless of whether the RBD is in the "up" or "down" state.

RBDs are shown in surface representation model with symmetry derived from the spike protein (PDB: 6VYB) to show their solvent accessible surface area in either "up" or "down" state. The buried surface area (BSA) was calculated by PISA program (Krissinel and Henrick, 2007) . Error bars indicate standard deviation (SD) of at least two biological replicates.

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ian A. Wilson (wilson@scripps.edu).

All reagents generated in this study are available from the Lead Contact (I.A.W.) with a completed Materials Transfer Agreement. 

The receptor-binding domain (RBD) (residues 319-541) of the SARS-CoV-2 spike (S) protein (GenBank: QHD43416.1), RBD (residues 306-527) of the SARS-CoV S protein (GenBank:

ABF65836.1), RBD (residues 315-537) of Guangdong pangolin-CoV (GenBank: QLR06866.1), and RBD (residues 319-541) of Bat-CoV RaTG13 (GenBank: QHR63300.2) were separately cloned into a customized pFastBac vector (Ekiert et al., 2011) , and fused with an N-terminal gp67 signal peptide and C-terminal His 6 tag (Yuan et al., 2020b) . Recombinant bacmids encoding each RBDs were generated using the Bac-to-Bac system (Thermo Fisher Scientific) followed by transfection into Sf9 cells using FuGENE HD (Promega) to produce baculoviruses for RBD expression. RBD proteins were expressed in High Five cells (Thermo Fisher Scientific) with suspension culture shaking at 110 r.p.m. at 28 ºC for 72 hours after the baculovirus transduction at an MOI of 5 to 10. Each supernatant containing RBD proteins were then concentrated using a 10 kDa MW cutoff Centramate cassette (Pall Corporation) followed by affinity chromatography using Ni-NTA resin (QIAGEN) and size exclusion chromatography using a HiLoad Superdex 200 pg column (Cytiva). The purified protein samples were buffer exchanged into 20 mM Tris-HCl pH 7.4 and 150 mM NaCl and concentrated for binding analysis and crystallographic studies. respectively. Epitope and paratope residues, as well as their interactions, were identified by using PISA program (Krissinel and Henrick, 2007) with buried surface area (BSA >0 Å 2 ) as the criterion.

The spike constructs used for negative-stain EM contain the mammalian codon-optimized gene and V705 were mutated to cysteines to introduce a disulfide for additional S stabilization. For the SARS-CoV spike protein, residues at 968 and 969 were replaced by prolines to generate stable spike proteins as described previously (Kirchdoerfer et al., 2018) . The spike plasmids were transfected into 293F cells and supernatant was harvested at 6 days post transfection.

Spike proteins were purified by running the supernatant through streptactin columns and then by size exclusion chromatography using Superose 6 increase 10/300 columns (Cytiva). Protein fractions corresponding to the trimeric spike protein were pooled and concentrated.

SARS-CoV-2 and SARS-CoV proteins were complexed with six molar excess of Fab for 1 hour prior to direct deposition onto carbon-coated 400-mesh copper grids. The EM grids were stained with 2 % (w/v) uranyl-formate for 90 seconds immediately following sample application. Grids were either imaged at 120 keV on a Tecnai T12 Spirit using a 4kx4k Eagle CCD. Micrographs were collected using Leginon (Suloway et al., 2005) and the images were transferred to Appion for processing. Particle stacks were generated in Appion (Lander et al., 2009) with particles picked using a difference-of-Gaussians picker (DoG-picker) . Particle stacks were then transferred to Relion (Zivanov et al., 2018) for 2D classification followed by 3D classification to sort well-behaved classes. Selected 3D classes were auto-refined on Relion and used to illustrate with UCSF Chimera (Pettersen et al., 2004) . A published prefusion spike model (PDB: 6Z97) (Huo et al., 2020) was used in our structural analysis.

Binding assays were performed by biolayer interferometry (BLI) using an Octet Red instrument The biosensors were transferred to wells containing either SARS-CoV-2 RBD or S-HexaPro proteins in kinetics buffer to allow for antigen association for 200 s followed by testing association of a second antibody Fab or ACE2 for 120 s.

To test whether binding of CV38-142 to SARS-CoV-2 RBD has an impact on the binding of ACE2, a surface plasma resonance (SPR) competition assay was performed on a Biacore T200 instrument (Cytiva) at 25 ºC. Biotinylated human ACE2 (residue 18-740, ACROBiosystems) was reversibly immobilized on a CAP sensor chip (Cytiva) using Biotin CAPture Kit (Cytiva).

CV38-142 IgG used in the SPR assay was produced in CHO cells and was kindly provided by Miltenyi Biotec, Bergisch Gladbach, Germany. were expressed in HEK293T cells and immobilized onto 96-well plates as previously described (Kreye et al., 2020) . Mutations were introduced by overlap extension PCR and confirmed by Sanger sequencing (LGC Genomics). Human anti-spike RBD monoclonal antibodies were applied at 1 μg/ml and detected using horseradish peroxidase (HRP)-conjugated anti-human IgG (Dianova) and the HRP substrate 1-step Ultra TMB (Thermo Fisher Scientific). HRPconjugated F(ab')2 anti-rabbit IgG (Dianova) was used to confirm the presence of immobilized antigens.

Pseudovirus preparation and assay were performed as previously described with minor modifications . Pseudovirions were generated by co-transfection of The MuSyC model fitting with the synergy program also gives two other parameters, namely synergistic efficacy (β) and synergistic cooperativity (γ) score (Wooten and Albert, 2020) . The β score denotes synergistic efficacy, which quantifies the percent change on the maximal efficacy of the antibody combination compared to the most efficacious single agent. The γ 12 score J o u r n a l P r e -p r o o f 29 denotes how the first antibody changes the second Hill slope, while γ 21 denotes how the second changes the first Hill slope.

Shape complementarity values (Sc) were calculated using SC program as described previously (Lawrence and Colman, 1993) .

The kinetics binding data were analyzed using Octet Data Analysis software version 12.0 (Sartorius). Pseudovirus neutralization data from at least two biological repeats were analyzed in Prism 9 (GraphPad) using "One Site -Fit LogIC50" regression model. Data are shown as mean ± SD. 2D matrix neutralization data were analyzed using synergy program (Wooten and Albert, 2020) 

PHENIX: a comprehensive Python-based system for macromolecular structure solution

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Conservation of water molecules in an antibody-antigen interaction

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

MolProbity: all-atom structure validation for macromolecular crystallography

Origin and evolution of pathogenic coronaviruses

Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy

A highly conserved neutralizing epitope on group 2 influenza A viruses

Coot: model-building tools for molecular graphics

Features and development of Coot

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Bat origin of human coronaviruses

Neutralization of SARS-CoV-2 by destruction of the prefusion spike

SynergyFinder: a web application for analyzing drug combination dose-response matrix data

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model

Inference of macromolecular assemblies from crystalline state

Shape complementarity and hydrogen bond preferences in protein-protein interfaces: implications for antibody modeling and protein-protein docking

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Appion: an integrated, database-driven pipeline to facilitate EM image processing

Shape complementarity at protein/protein interfaces

Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

COVID mink analysis shows mutations are not dangerous -yet

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Phaser crystallographic software

Quantifying drug combination synergy along potency and efficacy axes

Processing of X-ray diffraction data collected in oscillation mode

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

UCSF Chimera--a visualization system for exploratory research and analysis

Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

RELION: implementation of a Bayesian approach to cryo-EM structure determination

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

Automated molecular microscopy: the new Leginon system

Sixteen novel lineages of SARS-CoV-2 in South Africa

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Structural insights into coronavirus entry

Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy

Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia

Comprehensive analysis of the glycan complement of SARS-CoV-2 spike proteins using signature Ions-triggered electron-transfer/higher-energy collisional dissociation (EThcD) mass spectrometry

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Site-specific glycan analysis of the SARS-CoV-2 spike

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Possible hostadaptation of SARS-CoV-2 due to improved ACE2 receptor binding in mink

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Antibody-antigen interactions

synergy -A Python library for calculating, analyzing, and visualizing drug combination synergy

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain

Zoonotic origins of human coronaviruses

The role of hydrogen bonding via interfacial water molecules in antigen-antibody complexation. The HyHEL-10-HEL interaction

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Structural basis of a shared antibody response to SARS-CoV-2

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Potently neutralizing and protective human antibodies against SARS-CoV-2

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies

J o u r n a l P r e -p r o o f